← Leaderboards
Constantine G Lyketsos
Johns Hopkins University
$38,849,879
Attributed
$52,565,294
Total exposure
16
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.4M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$52,565,294 · 16
By mechanism
R01$37,461,303 · 7
P30$6,785,571 · 3
P50$6,080,791 · 3
U01$2,233,930 · 1
M01$3,699 · 2
Top collaborators
- Anton P Porsteinsson9 shared
- Andres M. Lozano6 shared
- Sid E O'Bryant5 shared
- Robert A Rissman5 shared
- Joann T Tschanz2 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Martin G Pomper$38,517,075
- Richard J Jones$17,555,212
- Gregory D Kirk$60,349,977
- William George Nelson$34,555,726
- Elizabeth Marion Jaffee$29,780,612
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposS DiseaseDementiaCognitiveCognitionClinical TrialsCooperative StudyBrainBloodParticipantClinical ResearchResearch PersonnelCaregiversSamplingSeveritiesBiologicalSafetyTherapy DevelopmentEnrollmentImpaired CognitionPlasmaNeurologicResponseEvaluation
Grant awards (60)
Core B: Clinical Core$1,049,789
P30 · FY2025 · AG · contact PI
Core B: Clinical Core$1,163,925
P30 · FY2024 · AG · contact PI
Core B: Clinical Core$1,241,732
P30 · FY2023 · AG · contact PI
Escitalopram for Agitation in Alzheimer Disease$2,959,649
R01 · FY2022 · AG · contact PI
Core B: Clinical Core$1,138,201
P30 · FY2022 · AG · contact PI
Escitalopram for Agitation in Alzheimer Disease$3,521,438
R01 · FY2021 · AG · contact PI
Core B: Clinical Core$1,260,738
P30 · FY2021 · AG · contact PI
Escitalopram for Agitation in Alzheimer Disease$332,357
R01 · FY2021 · AG · contact PI
The Coronavirus Pandemic, Caregiver Distress, And Neuropsychiatric Symptoms In Individuals With Alzheimer's Disease$332,237
R01 · FY2021 · AG · contact PI
Core B: Clinical Core$931,186
P30 · FY2020 · AG · contact PI
A Proinflammatory Endophenotype to Predict NSAID Treatment Response Alzheimer's Disease Clinical Trials$681,564
R01 · FY2020 · AG
A Proinflammatory Endophenotype to Predict NSAID Treatment Response Alzheimer's Disease Clinical Trials$813,603
R01 · FY2019 · AG
Core B: Clinical Core$572,607
P50 · FY2019 · AG · contact PI
Escitalopram for Agitation in Alzheimer Disease - Actigraph Supplement$379,256
R01 · FY2019 · AG · contact PI
Escitalopram for Agitation in Alzheimer Disease$3,011,794
R01 · FY2018 · AG · contact PI
A Proinflammatory Endophenotype to Predict NSAID Treatment Response Alzheimer's Disease Clinical Trials$681,543
R01 · FY2018 · AG
Core B: Clinical Core$573,387
P50 · FY2018 · AG · contact PI
Escitalopram for Agitation in Alzheimer Disease - Blood Biomarker Banking Supplement$120,368
R01 · FY2018 · AG · contact PI
Escitalopram for Agitation in Alzheimer Disease$3,000,455
R01 · FY2017 · AG · contact PI
A Proinflammatory Endophenotype to Predict NSAID Treatment Response Alzheimer's Disease Clinical Trials$681,438
R01 · FY2017 · AG
Core B: Clinical Core$572,924
P50 · FY2017 · AG · contact PI
Escitalopram for Agitation in Alzheimer Disease$3,183,018
R01 · FY2016 · AG · contact PI
A Proinflammatory Endophenotype to Predict NSAID Treatment Response Alzheimer's Disease Clinical Trials$742,047
R01 · FY2016 · AG
Core B: Clinical Core$572,607
P50 · FY2016 · AG · contact PI
Deep Brain Stimulation for Alzheimer's Disease$472,366
R01 · FY2016 · AG · contact PI
Deep Brain Stimulation for Alzheimer's Disease$609,940
R01 · FY2015 · AG · contact PI
Core B: Clinical Core$572,606
P50 · FY2015 · AG · contact PI
Exploring the relationship between cerebral glucose metabolism and change in cognition in the ADvance randomized control trial of Deep Brain Stimulation$4,662
R01 · FY2015 · AG · contact PI
Deep Brain Stimulation for Alzheimer's Disease$568,718
R01 · FY2014 · AG · contact PI
Deep Brain Stimulation for Alzheimer's Disease$541,855
R01 · FY2013 · AG · contact PI
Citalopram Treatment for Agitation in Alzheimer Dementia$1,372,242
R01 · FY2012 · AG · contact PI
Deep Brain Stimulation for Alzheimer's Disease$598,864
R01 · FY2012 · AG · contact PI
Citalopram Treatment for Agitation in Alzheimer Dementia$1,379,758
R01 · FY2011 · AG · contact PI
Progression of Dementia: A Population Study$1,438,268
R01 · FY2010 · AG
Citalopram Treatment for Agitation in Alzheimer Dementia$1,422,040
R01 · FY2010 · AG · contact PI
CLINICAL CORE$571,447
P50 · FY2010 · AG · contact PI
Progression of Dementia: A Population Study$1,555,326
R01 · FY2009 · AG
Citalopram Treatment for Agitation in Alzheimer Dementia$1,446,942
R01 · FY2009 · AG · contact PI
CLINICAL CORE$703,835
P50 · FY2009 · AG · contact PI
Citalopram Treatment for Agitation in Alzheimer Dementia$581,127
R01 · FY2009 · AG · contact PI
Citalopram Treatment for Agitation in Alzheimer Dementia$1,664,231
R01 · FY2008 · AG · contact PI
CLINICAL CORE$667,297
P50 · FY2008 · AG · contact PI
CLINICAL CORE$619,428
P50 · FY2007 · AG · contact PI
Depression in Alzheimer's Disease Study 2 (DIADS-2)$366,242
U01 · FY2007 · MH · contact PI
Depression in Alzheimer's Disease Study 2 (DIADS-2)$449,650
U01 · FY2006 · MH · contact PI
CLINICAL CORE$332,163
P50 · FY2006 · AG · contact PI
PHYSICAL ACTIVITY IN ALZHEIMER'S DISEASE PROGNOSIS: A CLINICAL TRIAL$822
M01 · FY2006 · RR · contact PI
Dementia and Psychiatric Disorders in Assisted Living$747,250
R01 · FY2005 · MH
Depression in Alzheimer's Disease Study 2 (DIADS-2)$463,988
U01 · FY2005 · MH
CLINICAL CORE$322,490
P50 · FY2005 · AG
PHYSICAL ACTIVITY IN ALZHEIMER'S DISEASE PROGNOSIS: A CLINICAL TRIAL$997
M01 · FY2005 · RR
Dementia and Psychiatric Disorders in Assisted Living$731,350
R01 · FY2004 · MH
Depression in Alzheimer's Disease Study 2 (DIADS-2)$452,785
U01 · FY2004 · MH
Physical Activity in Alzheimer's Disease prognosis: a clinical trial$1,880
M01 · FY2004 · RR
Dementia and Psychiatric Disorders in Assisted Living$759,986
R01 · FY2003 · MH
Depression in Alzheimer's Disease Study 2 (DIADS-2)$501,265
U01 · FY2003 · MH
DEMENTIA AND PSYCHIATRIC DISORDERS IN ASSISTED LIVING$385,986
R01 · FY2001 · MH
TREATMENT OF DEPRESSION IN ALZHEIMERS DISEASE$154,384
R01 · FY2001 · MH
DEMENTIA AND PSYCHIATRIC DISORDERS IN ASSISTED LIVING$363,740
R01 · FY2000 · MH
TREATMENT OF DEPRESSION IN ALZHEIMERS DISEASE$221,501
R01 · FY2000 · MH